Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

AbbVie (ABBV) is highlighted as a compelling long-term value stock, underpinned by its strategic $63 billion acquisition of Allergan in May 2020, which diversified its portfolio beyond Humira and introduced new growth drivers like Skyrizi and Rinvoq. Zacks rates ABBV as a #3 (Hold) with a 'B' VGM Score and a 'B' Value Style Score, citing an attractive forward P/E of 15.47. This positive outlook is reinforced by recent upward revisions to its FY2025 earnings estimates, now at $12.28 per share, and a consistent 2.6% average earnings surprise.

Analysis

AbbVie (ABBV) presents a compelling case for long-term value, primarily driven by its strategic transformation following the $63 billion acquisition of Allergan in May 2020. This move has successfully diversified its revenue base, mitigating the significant risk associated with the loss of patent protection for its former flagship product, Humira. The company's future growth is now anchored to its newer immunology drugs, Skyrizi and Rinvoq, which are positioned as key long-term drivers. From a valuation standpoint, the stock is flagged as attractive with a forward P/E ratio of 15.47, earning it a 'B' grade for Value from Zacks. While the official Zacks Rank is a #3 (Hold), this is counterbalanced by positive underlying indicators. Specifically, two analysts have revised their fiscal 2025 earnings estimates upward in the last 60 days, lifting the consensus estimate to $12.28 per share. Furthermore, AbbVie has a demonstrated history of performance, evidenced by an average earnings surprise of 2.6%.

Key Decisions for Investors

• Value-oriented investors should consider AbbVie's current valuation, supported by a forward P/E of 15.47 and a 'B' Value Score, as a potentially attractive entry point for a large-cap pharmaceutical holding.
• Investors should closely monitor the sales growth and market penetration of Skyrizi and Rinvoq, as the performance of these drugs is critical to validating the company's long-term growth thesis beyond the Humira patent cliff.
• Given the neutral Zacks #3 (Hold) rating, it is prudent to weigh the positive fundamentals, such as consistent earnings beats and upward estimate revisions, against the possibility of limited near-term catalysts for significant share price appreciation.